STAT3 and neoplasm: Preclinical studies indicate increased IL‐6/JAK/STAT3 signalling in tumour cells and tumour infiltrating immune cells could promote tumour proliferation, survival, invasion and metastasis, and might suppress anti‐tumour immunity.68